Mese: ottobre 2025

DelveInsight’s “Huntington’s Disease Pipeline Insight 2025” report offers in-depth analysis of over 20 companies and more than 20 pipeline drugs in the Huntington’s Disease treatment landscape. It features detailed profiles of Huntington’s Disease Pipeline drugs, covering both clinical and nonclinical development phases. Moreover, it assesses Huntington’s Disease pipeline therapeutics by product type, development stage, administration route, and molecular type. It also highlights discontinued pipeline products in this area.

Request a sample and discover the recent advances in Huntington’s Disease Treatment Drugs @ Huntington’s Disease Pipeline Outlook Report

Key Takeaways from the Huntington’s Disease Pipeline Report

On September 19, 2025, Azidus Brasil conducted a Phase II dose-response study where participants with HD will receive three intravenous injections of the investigational product or placebo (one every month for three months), totaling three cycles. The subjects will be randomized in a 2:2:1 ratio for the groups G1: lower dose (1×10^6 cells/weight range), G2: higher dose (2×10^6 cells/weight range), or G3: placebo. 

On September 18, 2025, Brainvectis, a subsidiary of Asklepios BioPharmaceutical, Inc. (AskBio) conducted a trial with 2 parts: Dose-Finding Part and Expansion Part; each part has 3 phases: Screening Phase (8 weeks, extendable to 12 weeks for scheduling), Treatment and Initial Follow-Up Phase (52 weeks), and Long-Term Follow-Up Phase (4 years). In the Dose-Finding Part, 2 dose titers will be tested in 3-6 subjects per cohort. Once a dose is selected based on Dose-Limiting Toxicities, an additional 6 subjects will be enrolled into the Dose Expansion Part. 

On September 15, 2025, Supernus Pharmaceuticals Inc. organized a study to evaluate the size of baseline differences between participants with early Huntington’s Disease (HD) and healthy participants (HP) regarding cognitive performance metrics. DelveInsight’s Huntington’s Disease pipeline report showcases a thriving field with over 20 active participants developing more than 20 pipeline therapies for Huntington’s Disease management. 

The leading Huntington’s Disease Companies include Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio, and others. 

Promising Huntington’s Disease Pipeline Therapies include Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others. 

Discover innovative advancements in Huntington’s Disease therapies! Obtain detailed information on key clinical trials, emerging drugs, and market prospects @ Huntington’s Disease Clinical Trials Assessment

The Huntington’s Disease Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Huntington’s Disease Pipeline Report also emphasizes the unmet needs related to Huntington’s Disease.

Huntington’s Disease Overview

Huntington’s disease is a hereditary, progressive, neurodegenerative condition characterized by the gradual onset of involuntary muscle movements affecting the hands, feet, face, and trunk, along with progressive decline in cognitive processes and memory (dementia). This condition causes alterations in the central brain region, impacting movement, mood, and thinking abilities. Symptoms of Huntington’s disease typically appear between ages 30 and 50, but can start as early as age 2 or as late as 80.

Huntington’s Disease Emerging Drugs Profile

RG6042: Hoffmann-La Roche Tominersen (ASO-HTT, RG6042) is an antisense drug in development for Huntington’s disease treatment. Tominersen is engineered to decrease the production of all forms of the huntingtin (HTT) protein, where its mutated variant (mHTT) is responsible for Huntington’s disease. The drug is currently in Phase III clinical trials for Huntington’s disease.

PTC518: PTC Therapeutics PTC518, an orally administered small molecule, lowers the production of the mutated Huntingtin protein that causes neuronal injury and death, resulting in disease progression. The orally bioavailable small molecule crosses the blood-brain barrier, is selective, adjustable, and not effluxed. The drug is in Phase II clinical trials for Huntington’s disease.

ALN-HTT02: Alnylam Pharmaceuticals ALN-HTT02 is an innovative therapeutic strategy for Huntington’s disease from Alnylam Pharmaceuticals. This drug is a small interfering RNA (siRNA) aimed at reducing huntingtin protein production, which is linked to the disease’s pathology. It functions by targeting a specific HTT gene messenger RNA (mRNA) region, facilitating its breakdown and thus blocking the synthesis of both normal and mutant huntingtin proteins. Delivered via intrathecal injection. The drug is in Phase I clinical trials for Huntington’s disease.

Stay updated on Huntington’s Disease pipeline trends! Reveal important developments in therapeutic innovations and their potential effects on patients and healthcare @ Huntington’s Disease Unmet Needs

The Huntington’s Disease Pipeline Report Provides Insights into

The report offers detailed information on companies developing therapies for Huntington’s Disease, including the total therapies each company is advancing. It reviews various therapeutic candidates divided into early-stage, mid-stage, and late-stage development for Huntington’s Disease treatment. Huntington’s Disease Companies are focused on targeted therapeutics with active and inactive (dormant or discontinued) projects. Huntington’s Disease Drugs in development, categorized by development stage, administration route, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular type. In-depth analysis of collaborations (company-to-company and company-academia partnerships), licensing agreements, and financing details to support future progress in the Huntington’s Disease market Huntington’s Disease Companies

Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio, and others.

Huntington’s Disease pipeline report evaluates the therapeutic potential of pipeline drugs by Route of Administration. Products are classified under various ROAs, such as

Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Huntington’s Disease Products have been categorized under various Molecule types, such as

Oligonucleotide Peptide Small molecule Transform your understanding of the Huntington’s Disease Pipeline! See the latest progress in drug development and clinical research @ Huntington’s Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Huntington’s Disease Pipeline Report

Coverage- Global 

Huntington’s Disease Companies- Hoffmann-La Roche, PTC Therapeutics, Annexon, Alnylam Pharmaceuticals, Neuvivo, BPG Bio, and others. 

Huntington’s Disease Pipeline Therapies- Dimebon, Pridopidine, SAGE-718, Tominersen 60 mg, AB-1001, ISIS 443139 10 mg, ER2001 injection, and others. 

Huntington’s Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Huntington’s Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

Stay Ahead in Genetic Disorders Research–Access the Full Huntington’s Disease Pipeline Analysis Today! @ Huntington’s Disease Drugs and Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Huntington’s Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Huntington’s Disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. RG6042: Hoffmann-La Roche
9. Mid Stage Products (Phase II)
10. PTC518: PTC Therapeutics
11. Early Stage Products (Phase I)
12. ALN-HTT02: Alnylam Pharmaceuticals
13. Mid Stage Products (Phase II)
14. Preclinical Stage Products
15. Drug Name: Company Name
16. Inactive Products
17. Huntington’s Disease – Collaborations Assessment- Licensing / Partnering / Funding
18. Huntington’s Disease – Unmet Needs
19. Huntington’s Disease – Market Drivers and Barriers
20. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Sepsis Pipeline Insight 2025” report offers in-depth analysis of over 25 companies and more than 30 pipeline drugs in the Sepsis treatment landscape. It features detailed profiles of Sepsis pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses Sepsis pipeline therapeutics by product type, development stage, administration route, and molecular type. It also highlights discontinued pipeline products in this area.

Interested in the newest developments in the Sepsis Pipeline? Click here to discover the treatments and studies gaining attention @ Sepsis Pipeline Outlook Report

Key Takeaways from the Sepsis Pipeline Report

On October 8, 2025, Regeneron Pharmaceuticals conducted a trial exploring an experimental drug named REGN7544 (referred to as “study drug”). The trial targets adult patients (aged 18 to 85) hospitalized for a severe infection (known as “sepsis”) and receiving standard-of-care drugs for low blood pressure (called “vasopressors”) due to sepsis. 

The objective is to evaluate the safety, tolerability, and efficacy of the study drug by tracking its impact on blood pressure and the overall vasopressor dosage during the hospital stay. DelveInsight’s Sepsis Pipeline report showcases a thriving field with over 25 active participants developing more than 30 pipeline therapies for Sepsis management. 

The leading Sepsis Companies include AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics, and others. 

Promising Sepsis Therapies include Cefiderocol, Daptomycin, E5564, Meropenem, STC314 Injection, Thymosin alpha 1, Ubiquinol, Drotrecogin alfa, Resatorvid, sPLA2 Inhibitor, and others. 

Want to know which companies are driving innovation in Sepsis? Explore the comprehensive pipeline insights @ Sepsis Clinical Trials Assessment

The Sepsis Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Sepsis Pipeline Report also emphasizes the unmet needs related to Sepsis.

Sepsis Overview

Sepsis is a life-threatening organ dysfunction arising from a dysregulated host response to infection. Sepsis is sometimes termed septicemia or blood poisoning. If not detected early, it can escalate to septic shock, multiple organ failure, and death. It is most commonly a severe complication of infection, particularly in low- and middle-income countries where it is a significant cause of maternal and neonatal morbidity and mortality. Sepsis arises when the immune system releases chemicals into the bloodstream to fight an infection, triggering widespread inflammation throughout the body instead.

Sepsis Emerging Drugs Profile

Enibarcimab: AdrenoMed AG Enibarcimab (HAM8101; former name: Adrecizumab) is a clinical-stage, pioneering drug addressing loss of vascular integrity. The compelling rationale for Enibarcimab is supported by the elegance of its mode of action, a monoclonal antibody that, upon binding to its target Adrenomedullin, maintains its function as a regulator of vascular integrity. Enibarcimab targets Adrenomedullin (ADM), a vasoprotective peptide hormone. ADM that persists in the bloodstream, however, exerts a different effect, aiding in alleviating sepsis: enhancing endothelial barrier stability by repairing cell junctions between endothelial cells that typically control molecule transport and leakage. In healthy conditions, ADM levels in the bloodstream and extravascular space are balanced to preserve endothelial barrier integrity and normal blood pressure. The drug is currently in Phase II development for sepsis.

M 6229: Matisse Pharmaceuticals Matisse’s platform technology is rooted in the finding that in numerous sepsis patients, proteins known as histones are released by the innate immune system and into dying cells into the blood, where they damage other cells. Due to a self-perpetuating cycle, individuals may perish from organ failure within one or two days. Preclinical results have shown that neutralizing toxic histones with Matisse’s product M6229 stops the harmful cycle by counteracting cationic histones with anionic M6229. Matisse asserts to have developed an elegant solution for managing one of sepsis’s major complications by employing a non-anticoagulant heparin fraction called M6229 to neutralize toxic circulating histones. The drug is in Phase II trials for sepsis.

SNIPR 001: SNIPR Biome SNIPR001 is a novel, orally-delivered antibiotic crafted to precisely target challenging bacterial infections. It is created using SNIPR Biome’s CRISPR-Guided Vectors™ (CGV™ Technology), designed to introduce CRISPR reagents into target bacterial cells. SNIPR001 is engineered to attack specific E. coli bacteria in the gut and block their migration to the bloodstream, without disrupting beneficial microbiome bacteria. It incorporates four CRISPR-armed phages that selectively target and eradicate E. coli strains resistant to fluoroquinolone, with proven effectiveness in animal disease models. The drug is in preclinical development for sepsis.

If you’re monitoring ongoing Sepsis Clinical trials, this press release is essential. Tap to view the advancements @ Sepsis Treatment Drugs

Sepsis Companies

AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics, and others.

The Sepsis Pipeline report provides insights into

The report offers detailed information on companies developing therapies for Sepsis, including the total therapies each company is advancing. It reviews various therapeutic candidates divided into early-stage, mid-stage, and late-stage development for Sepsis treatment. Sepsis Companies are focused on targeted therapeutics with active and inactive (dormant or discontinued) projects. Sepsis Drugs in development, categorized by development stage, administration route, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular type. In-depth analysis of collaborations (company-to-company and company-academia partnerships), licensing agreements, and financing details to support future progress in the Sepsis market. Sepsis pipeline report evaluates the therapeutic potential of pipeline drugs by Route of Administration. Sepsis Products are classified under various ROAs, such as

Oral Intravenous Subcutaneous Parenteral Topical Sepsis Products have been categorized under various Molecule types, such as

Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy From emerging drug candidates to competitive intelligence, the Sepsis Pipeline Report covers everything – check it out now @ Sepsis Market Drivers and Barriers, and Future Perspectives

Scope of the Sepsis Pipeline Report

Coverage- Global 

Sepsis Companies- AdrenoMed AG, Matisse Pharmaceuticals, SNIPR Biome, Tianjin Chase Sun Pharmaceutical, Beijing Scitech-Mq Pharmaceuticals, Recce Pharmaceuticals, Inotrem, Octapharma, Shaperon, Shionogi, Pharmazz, Seres Therapeutics, and others. 

Sepsis Therapies- Cefiderocol, Daptomycin, E5564, Meropenem, STC314 Injection, Thymosin alpha 1, Ubiquinol, Drotrecogin alfa, Resatorvid, sPLA2 Inhibitor, and others. Sepsis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination 

Sepsis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

Stay ahead in Healthcare Research – discover what’s next for the Sepsis Treatment landscape in this detailed analysis @ Sepsis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Sepsis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Sepsis– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug Name: Company Name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Enibarcimab: AdrenoMed AG
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. SNIPR 001: SNIPR Biome
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Sepsis Key Companies
21. Sepsis Key Products
22. Sepsis- Unmet Needs
23. Sepsis- Market Drivers and Barriers
24. Sepsis- Future Perspectives and Conclusion
25. Sepsis Analyst Views
26. Sepsis Key Companies
27. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Knee Osteoarthritis Pipeline Insight 2025” report offers in-depth analysis of over 50 companies and more than 60 pipeline drugs in the Knee Osteoarthritis treatment landscape. It includes detailed profiles of Knee Osteoarthritis Pipeline drugs, spanning clinical and nonclinical development phases. Moreover, it evaluates Knee Osteoarthritis Pipeline Therapeutics by product type, development stage, administration route, and molecular type. It also highlights discontinued pipeline products in this area.

Interested in the newest developments in the Knee Osteoarthritis Pipeline? Click here to discover the treatments and studies gaining attention @ Knee Osteoarthritis Pipeline Outlook Report

Key Takeaways from the Knee Osteoarthritis Pipeline Report

On September 30, 2025, ArthroBiologix Inc. conducted a trial to assess if patient outcomes for intra-articular platelet-rich plasma (PRP) injections in knee osteoarthritis are affected by witnessing the procedure’s preparatory steps. Observing the PRP administration process might boost treatment efficacy compared to those who do not view the preparatory steps. 

On September 3, 2025, Synartro AB organized a Phase 1/2a Study to evaluate Safety, Tolerability, Systemic Exposure, and Initial Efficacy of Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis. 

DelveInsight’s Knee Osteoarthritis Pipeline report illustrates a thriving field with over 50 active participants developing more than 60 pipeline therapies for Knee Osteoarthritis management.

The leading Knee Osteoarthritis Companies include Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia, among others. 

Promising Knee Osteoarthritis Therapies include Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599, and others. 

Want to know which companies are driving innovation in Knee Osteoarthritis? Explore the comprehensive pipeline insights @ Knee Osteoarthritis Clinical Trials Assessment

The Knee Osteoarthritis Pipeline Report provides disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Knee Osteoarthritis Pipeline Report also emphasizes the unmet needs related to Knee Osteoarthritis.

Knee Osteoarthritis Overview

Osteoarthritis (OA) is the most widespread form of arthritis. Some call it degenerative joint disease or “wear and tear” arthritis. It most commonly affects the hands, hips, and knees. In OA, the cartilage inside a joint starts to deteriorate, and the underlying bone begins to change. These alterations typically occur gradually and worsen over time. OA can cause pain, stiffness, and swelling. In certain instances, it leads to reduced function and disability; some people can no longer perform daily tasks or work.

Knee Osteoarthritis Emerging Drugs Profile

Lorecivivint: Biosplice Therapeutics Lorecivivint (SM04690) is a small-molecule inhibitor of CLK/DYRK1A that influences Wnt and inflammatory pathways and is being developed as a potential disease-modifying osteoarthritis treatment. Preclinical data controlled with vehicles suggest lorecivivint has a dual mechanism with three possible impacts on joint health: reducing inflammation, decelerating cartilage degradation, and promoting cartilage formation. The drug is currently in Phase III development for Knee Osteoarthritis.

EP-104IAR: Eupraxia Pharmaceuticals Inc EP-104IAR is engineered to address the substantial unmet medical need and market demand for prolonged disease relief in various conditions benefiting from highly targeted and extended corticosteroid delivery. The primary indication is pain alleviation in knee OA. With EP-104IAR, Eupraxia aims to revolutionize knee OA pain treatment. Existing corticosteroids are highly effective at reducing pain for a brief period late in the disease but can subject the body to undesirable local and systemic side effects. EP-104IAR is designed to extend pain relief duration with reduced unwanted effects. It encloses a highly potent corticosteroid (fluticasone propionate) within a microns-thin polymer membrane, part of Eupraxia’s patented technology platform. Injected into the knee, EP-104IAR is intended to release the corticosteroid gradually into the knee joint, delivering local therapeutic levels for up to six months. This offers the potential benefits of longer pain relief with fewer systemic side effects. A strong safety and tolerability profile would also help the estimated 70% of knee OA patients with pain in both knees by enabling treatment of both affected joints simultaneously. The drug is in Phase II trials for Knee Osteoarthritis.

LG00034053: LG Chem LG34053 is an injectable novel drug with a unique approach of inhibiting the inflammatory pathway and preventing chondrocyte apoptosis. LG Chem anticipates that this new drug will differ from current symptomatic pain relief medications. LG00034053 is the first injection-type novel drug worldwide that blocks inflammatory pathways and prevents cartilage cell death. Preclinical findings indicated that pain relief lasted several months with a single administration, and it also showed improvements in cartilage damage, the underlying cause of arthritis. It demonstrated potential for a novel drug distinct from existing symptomatic pain relief treatments. The drug is in Phase I/II trials for Knee Osteoarthritis.

If you’re monitoring ongoing Knee Osteoarthritis Clinical trials, this press release is essential. Tap to view the advancements @ Knee Osteoarthritis Treatment Drugs

The Knee Osteoarthritis Pipeline report provides insights into:-

The report offers detailed information on companies developing therapies for Knee Osteoarthritis, including the total therapies each company is advancing. It reviews various therapeutic candidates divided into early-stage, mid-stage, and late-stage development for Knee Osteoarthritis treatment. Knee Osteoarthritis Companies are focused on targeted therapeutics with active and inactive (dormant or discontinued) projects. Knee Osteoarthritis Drugs in development, categorized by development stage, administration route, target receptor, monotherapy or combination therapy, distinct mechanism of action, and molecular type. In-depth analysis of collaborations (company-to-company and company-academia partnerships), licensing agreements, and financing details to support future progress in the Knee Osteoarthritis market. Knee Osteoarthritis Companies

Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia, among others.

Knee Osteoarthritis Pipeline report evaluates the therapeutic potential of pipeline drugs by Route of Administration. Products are classified under various ROAs, such as

Oral Intravenous Subcutaneous Parenteral Topical Knee Osteoarthritis Products have been categorized under various Molecule types, such as

Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy From emerging drug candidates to competitive intelligence, the Knee Osteoarthritis Pipeline Report covers everything – check it out now @ Knee Osteoarthritis Market Drivers and Barriers, and Future Perspectives

Scope of the Knee Osteoarthritis Pipeline Report

Coverage- Global 

Knee Osteoarthritis Companies- Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, and PT. Prodia Stem Cell Indonesia, among others. 

Knee Osteoarthritis Therapies- Civamide, SYN321, Clodronate, LBSA0103, Pelubiprofen CR 45mg tab., Tirzepatide, CLS2901C, RN624 (PF-04383119), Allocetra, RHH646, TLC599, and others. 

Knee Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination 

Knee Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

Stay ahead in Healthcare Research – discover what’s next for the Knee Osteoarthritis Treatment landscape in this detailed analysis @ Knee Osteoarthritis Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Knee Osteoarthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Knee Osteoarthritis – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Lorecivivint: Biosplice Therapeutics
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. EP-104IAR: Eupraxia Pharmaceuticals Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. LG00034053: LG Chem
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Knee Osteoarthritis Key Companies
21. Knee Osteoarthritis Key Products
22. Knee Osteoarthritis Unmet Needs
23. Knee Osteoarthritis Market Drivers and Barriers
24. Knee Osteoarthritis Future Perspectives and Conclusion
25. Knee Osteoarthritis Analyst Views
26. Knee Osteoarthritis Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Diabetic Retinopathy Pipeline Insights 2025” report delivers extensive analysis on over 50 companies and more than 55 pipeline drugs in the Diabetic Retinopathy treatment arena. It includes thorough profiles of Diabetic Retinopathy pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Diabetic Retinopathy pipeline therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Explore the thorough insights from DelveInsight and stay updated on the Diabetic Retinopathy Treatment Landscape. Click here to learn more @ Diabetic Retinopathy Pipeline Outlook

Key Takeaways from the Diabetic Retinopathy Pipeline Report

On October 3, 2025, Jaeb Center for Health Research conducted a trial to assess long-term visual acuity, along with variations in injection numbers, procedures, and complications post-randomization treatment, plus cost factors. 

On October 2, 2025, Boehringer Ingelheim disclosed a trial to determine if BI 764524 benefits individuals with diabetic retinopathy. The study also seeks to establish an appropriate dosing schedule for BI 764524. Participants are randomly assigned to 5 groups. Those in groups 1, 2, and 3 receive BI 764524. Over 1 year, they get varying numbers of injections of the same dose into one eye. At certain visits, participants may receive a sham control, mimicking an injection without a needle, so they remain unaware of the actual BI 764524 injections. 

On October 2, 2025, Jaeb Center for Health Research launched a trial to test the practicality of a model where ophthalmologists prescribe or partner with primary care providers like internists/endocrinologists to administer and monitor fenofibrate safely. If this trial proves fenofibrate effective in reducing proliferative diabetic retinopathy (PDR) onset, and if adopted by retina specialists, it could introduce a broad strategy to avert vision-threatening diabetes complications. DelveInsight’s Diabetic Retinopathy pipeline report illustrates a vibrant arena with over 50 active contributors developing more than 55 pipeline treatments for Diabetic Retinopathy care. 

The prominent Diabetic Retinopathy Companies include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. 

Promising Diabetic Retinopathy Pipeline Therapies include Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. 

Discover innovative advancements in Diabetic Retinopathy therapies! Obtain detailed information on key Diabetic Retinopathy clinical trials, emerging drugs, and market prospects @ Diabetic Retinopathy Clinical Trials Assessment

The Diabetic Retinopathy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Diabetic Retinopathy Pipeline Report also highlights the unmet needs with respect to the Diabetic Retinopathy.

Diabetic Retinopathy Overview

Diabetic retinopathy is a diabetes-related eye complication stemming from harm to the blood vessels in the retina’s light-sensitive tissue. Initially, it may show no signs or mild vision issues, but can progress to blindness. It can affect anyone with type 1 or type 2 diabetes. The risk rises with diabetes duration and poor blood sugar control. The disease’s mechanisms involve chronic high blood sugar, activation of pathways like the polyol and protein kinase C, elevated growth factors such as vascular endothelial growth factor (VEGF), oxidative stress, and inflammation.

Diabetic Retinopathy Emerging Drugs Profile

Tarcocimab tedromer: Kodiak Sciences Tarcocimab is an experimental anti-VEGF treatment based on Kodiak’s proprietary Antibody Biopolymer Conjugate (“ABC”) Platform, engineered to sustain potent drug levels in ocular tissues longer than current options. Kodiak aims to enable earlier intervention and prevention of vision loss in diabetic retinopathy patients and create a new long-lasting agent to enhance results for retinal vascular conditions. The drug is currently in Phase III clinical trials for diabetic retinopathy.

OTT166: Ocuterra Therapeutics Nesvategrast (OTT166) is an experimental, novel, patented, potent and selective small molecule RGD integrin inhibitor crafted to balance physiochemical properties for high retinal concentration via topical (eye drop) application. In preclinical studies, nesvategrast selectively blocked key RGD integrin subtypes, including αvβ3, to modulate responses to VEGF and other growth factors driving diabetic retinopathy and related eye diseases. Early clinical trials in diabetic retinal disease patients showed initial tolerability and biological effects. The drug is in Phase II clinical trials for Diabetic retinopathy.

APX3330: Apexian Pharmaceuticals APX3330 is a pioneering, small molecule, oral inhibitor of the transcription factor regulator Ref-1 (reduction-oxidation effector factor-1). With a unique dual action, APX3330 inhibits pathways involving angiogenesis (VEGF) and inflammation (NFkB) to reduce abnormal activation of both processes linked to ocular conditions like DR, DME, and age-related macular degeneration (AMD). APX3330 has demonstrated a positive safety and tolerability profile in 12 trials involving healthy, hepatitis, cancer, and diabetic subjects. The drug is in Phase II clinical trials for diabetic retinopathy.

OTX-TKI: Ocular Therapeutix

OTX-TKI is an experimental bioresorbable, hydrogel implant containing axitinib, a small molecule, multi-target, tyrosine kinase inhibitor with anti-angiogenic effects, under evaluation for wet age-related macular degeneration (wet AMD) and other retinal disorders. The drug is currently in Phase I clinical trials for Diabetic retinopathy.

Stay updated on Diabetic Retinopathy pipeline trends! Reveal important developments in therapeutic innovations and their potential effects on patients and healthcare @ Diabetic Retinopathy Unmet Needs

The Diabetic Retinopathy Pipeline report provides insights into

The report furnishes comprehensive details on organizations advancing therapies for Diabetic Retinopathy, including the total treatments each company is developing. It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Diabetic Retinopathy management. Diabetic Retinopathy Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives. Diabetic Retinopathy Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category. Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Diabetic Retinopathy market Diabetic Retinopathy Companies

Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.

Diabetic Retinopathy pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

Oral Intravenous Subcutaneous Parenteral Topical Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as

Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Transform your understanding of the Diabetic Retinopathy Pipeline! See the latest progress in drug development and clinical research @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspectives

Scope of the Diabetic Retinopathy Pipeline Report

Coverage- Global 

Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others. 

Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others. 

Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination 

Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective

Table of Contents

1. Introduction
2. Executive Summary
3. Diabetic Retinopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Retinopathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. KSI-301: Kodiak Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RGX 314: Regenxbio Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OTX-TKI: Ocular Therapeutix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Retinopathy Key Companies
21. Diabetic Retinopathy Key Products
22. Diabetic Retinopathy- Unmet Needs
23. Diabetic Retinopathy- Market Drivers and Barriers
24. Diabetic Retinopathy- Future Perspectives and Conclusion
25. Diabetic Retinopathy Analyst Views
26. Diabetic Retinopathy Key Companies
27. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Influenza Pipeline Insight 2025” report delivers extensive analysis on over 120 companies and more than 120 pipeline drugs in the Influenza treatment arena. It includes thorough profiles of Influenza Pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Influenza Pipeline Therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Curious about the latest updates in the Influenza Pipeline? Click here to explore the therapies and trials making headlines @ Influenza Pipeline Outlook Report

Key Takeaways from the Influenza Pipeline Report

On September 22, 2025, Eurofarma Laboratorios S.A. conducted a Phase 3, multicenter, randomized, double-blind, comparative clinical trial to assess the combination of paracetamol 500mg + Fexofenadine 60mg + Phenylephrine 20mg for flu and common cold management. 

On September 12, 2025, Sanofi Pasteur disclosed a trial to supply sera (from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research (CBER) for additional analysis by the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA) to inform recommendations for future influenza vaccines. 

DelveInsight’s Influenza Pipeline report illustrates a vibrant arena with over 120 active contributors developing more than 120 pipeline treatments for Influenza care. The prominent Influenza Companies include Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, and others. Promising Influenza Therapies include Fluviral®, Varicella vaccine+TIV, Peramivir, Fluzone, Fluarix Tetra, VXA-A1.1, and others. 

Want to know which companies are leading innovation in Influenza? Dive into the full pipeline insights @ Influenza Clinical Trials Assessment

The Influenza Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Influenza Pipeline Report also highlights the unmet needs with respect to the Influenza.

Influenza Overview

Influenza, among the most widespread infectious illnesses, is a highly transmissible airborne condition that appears in seasonal outbreaks, presenting as an acute feverish ailment with varying systemic symptoms, from mild exhaustion to respiratory collapse and fatality. Influenza results in substantial work absences, human distress, and deaths. The CDC reported that seasonal influenza caused 24,000 to 62,000 fatalities in the 2019-2020 season.

Influenza Emerging Drugs Profile

mRNA-1010: Moderna mRNA-1010 is a vaccine candidate encoding hemagglutinin (HA) glycoproteins from the four influenza strains advised by the World Health Organization (WHO) for influenza prevention, including influenza A/H1N1, A/H3N2, and influenza B/Yamagata- and B/Victoria-lineages. HA serves as a key influenza surface glycoprotein, vital for broad protection, and is the main focus of existing influenza vaccines. It is currently in Phase III clinical trials for Seasonal Influenza.

SAB-176: SAB Biotherapeutics SAB-176 is a quadrivalent broadly neutralizing fully-human polyclonal antibody therapeutic candidate harnessing the human immune response for treating hospitalized patients with severe seasonal influenza. Developed via the company’s proprietary DiversitAb™ platform, it targets Type A and Type B influenza viruses. Preclinical data indicates SAB-176 may offer extensive protection against various influenza strains. As a potent polyclonal antibody therapy for severe seasonal influenza, it could address critically ill patients and deliver protective antibodies for vulnerable groups like the elderly and immunocompromised.

INNA-051: ENA Respiratory Pty Ltd INNA-051 is a broad-spectrum antiviral immunomodulatory nasal spray in clinical development for pre- and post-exposure prevention of respiratory viral infections in at-risk populations. Given its mechanism and delivery method, INNA-051 could tackle multiple viral respiratory pathogens across diverse patient groups with various comorbidities. INNA-051’s antiviral effectiveness is under evaluation in a Phase 2a influenza-challenge study in healthy volunteers.

CODA-VAX H1N1: Codagenix Codagenix has employed a design platform to create a live-attenuated, universal flu vaccine, CodaVax™-H1N1. The vaccine presents conserved antigens from the wild-type virus, showing universal potential in primate models and the ability to offer multi-season protection when expanded to its final quadrivalent version. It is currently in Phase I clinical trials for Influenza virus infections.

ALVR106: AlloVir ALVR106 is an allogeneic, off-the-shelf, multi-virus specific VST therapy candidate targeting diseases from respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV). In vitro data shows ALVR106 reactive cells exhibit antiviral effects against each targeted virus with little to no impact on uninfected cells. This preclinical evidence supports the antiviral benefits and safety of ALVR106 in patients.

If you’re tracking ongoing Influenza Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Influenza Treatment Drugs

The Influenza Pipeline report provides insights into:-

The report furnishes comprehensive details on organizations advancing therapies for Influenza, including the total treatments each company is developing. It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Influenza management. Influenza Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives. Influenza Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category. Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Influenza market. Influenza Companies

Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, and others.

Influenza Pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Influenza Products have been categorized under various Molecule types such as

Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine From emerging drug candidates to competitive intelligence, the Influenza Pipeline Report covers it all – check it out now @ Influenza Market Drivers and Barriers, and Future Perspectives

Scope of the Influenza Pipeline Report

Coverage- Global 

Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, and others.

 Influenza Therapies- Fluviral®, Varicella vaccine+TIV, Peramivir, Fluzone, Fluarix Tetra, VXA-A1.1, and others. 

Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III 

Stay ahead in Healthcare Research – discover what’s next for the Influenza Treatment landscape in this detailed analysis @ Influenza Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Influenza: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Influenza – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. mRNA-1010: Moderna
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. INNA-051: ENA Respiratory Pty Ltd
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. CODA-VAX H1N1: Codagenix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Influenza Key Companies
21. Influenza Key Products
22. Influenza- Unmet Needs
23. Influenza- Market Drivers and Barriers
24. Influenza- Future Perspectives and Conclusion
25. Influenza Analyst Views
26. Influenza Key Companies
27. Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Open-angle Glaucoma Pipeline Insight 2025” report delivers extensive analysis on over 18 companies and more than 20 pipeline drugs in the Open-angle Glaucoma treatment arena. It includes thorough profiles of Open-angle Glaucoma Pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Open-angle Glaucoma Pipeline Therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Curious about the latest updates in the Open-angle Glaucoma Pipeline? Click here to explore the therapies and trials making headlines @ Open-angle Glaucoma Pipeline Outlook Report

Key Takeaways from the Open-angle Glaucoma Pipeline Report

• On September 19, 2025, IVIEW Therapeutics Inc. disclosed a trial where subjects will range from 18 to 65 years old (inclusive) and have been diagnosed with primary open-angle glaucoma (POAG) for at least one year. Only those who give informed consent before all screening procedures can join the study.
• On September 19, 2025, AbbVie conducted a Phase 1/2 Study to assess the safety and effectiveness of AGN-193408 SR in individuals with Open-Angle Glaucoma or Ocular Hypertension.
• DelveInsight’s Open-angle Glaucoma Pipeline report illustrates a vibrant arena with over 18 active contributors developing more than 20 pipeline treatments for Open-angle Glaucoma care.
• The prominent Open-angle Glaucoma Companies include Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others.
• Promising Open-angle Glaucoma Therapies include Citicoline eye drops 2%, VVN539 Ophthalmic Solution 0.02%, XEN45 (Glaucoma Gel Stent), Travoprost, NCX 470, and others.

Want to know which companies are leading innovation in Open-angle Glaucoma? Dive into the full pipeline insights @ Open-angle Glaucoma Clinical Trials Assessment

The Open-angle Glaucoma Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Open-angle Glaucoma Pipeline Report also highlights the unmet needs with respect to the Open-angle Glaucoma.

Open-angle Glaucoma Overview

Open-angle glaucoma (OAG) represents the most common type of glaucoma, marked by a slow rise in intraocular pressure (IOP) that causes optic nerve harm. In contrast to other glaucoma types, the drainage angle in OAG stays open, but the trabecular meshwork where fluid drains becomes partly obstructed. This obstruction leads to pressure accumulation within the eye, gradually harming optic nerve fibers and causing vision impairment. The condition is frequently without symptoms in early phases, earning it the nickname “the silent thief of sight.”

Open-angle Glaucoma Emerging Drugs Profile

• NCX 470: Nicox Ophthalmics

NCX 470 is an innovative, next-generation nitric oxide (NO)-releasing prostaglandin analog developed by Nicox Ophthalmics. NCX-470 may benefit glaucoma patients through a mechanism beyond just IOP reduction, particularly by improving ocular blood flow. While IOP lowering is the standard treatment, initial research indicates that if approved, NCX-470’s combined approach (nitric oxide release and prostaglandin F2 activity) could position it as the most potent single-agent glaucoma medication for IOP reduction. The drug is currently in Phase III clinical trials for open-angle glaucoma or ocular hypertension.

• BTQ-1902: Betaliq, Inc.

BTQ 1902 is an EyeSol formulation of timolol, the most widely used beta blocker. Beta blockers form a key class of medications for glaucoma treatment. They lower Intraocular Pressure (IOP) by inhibiting sympathetic nerve endings in the ciliary epithelium, reducing aqueous humor production. Beta blockers are frequently used alongside other glaucoma drugs. The drug is in Phase II clinical trials for Open-Angle Glaucoma Treatment.

• TO-O-1001: Theratocular Biotek

TO-O-1001 (MG-O-1001) eye drops is a patented advanced Rho kinase (ROCK) inhibitor for treating individuals with primary open-angle glaucoma or ocular hypertension. Its effectiveness stems from a dual-targeting approach, relaxing trabecular meshwork cells and Schlemm’s canal inner walls. This boosts aqueous humor outflow, essential for lowering intraocular pressure. Preclinical studies in animals showed enhanced IOP reduction. The drug is in Phase I/II development for open-angle glaucoma or ocular hypertension.

If you’re tracking ongoing Open-angle Glaucoma Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Open-angle Glaucoma Treatment Drugs

The Open-angle Glaucoma Pipeline report provides insights into:-

• The report furnishes comprehensive details on organizations advancing therapies for Open-angle Glaucoma, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Open-angle Glaucoma management.
• Open-angle Glaucoma Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Open-angle Glaucoma Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Open-angle Glaucoma market.

Open-angle Glaucoma Companies

Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others.

Open-angle Glaucoma Pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Open-angle Glaucoma Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

From emerging drug candidates to competitive intelligence, the Open-angle Glaucoma Pipeline Report covers it all – check it out now @ Open-angle Glaucoma Market Drivers and Barriers, and Future Perspectives

Scope of the Open-angle Glaucoma Pipeline Report

• Coverage- Global
• Open-angle Glaucoma Companies- Nicox Ophthalmics, Betaliq, Inc., Qlaris Bio, Aerpio Pharmaceuticals, Theratocular Biotek, PolyActiva Pty Ltd., Whitecap Biosciences, JeniVision, EMS, and others.
• Open-angle Glaucoma Therapies- Citicoline eye drops 2%, VVN539 Ophthalmic Solution 0.02%, XEN45 (Glaucoma Gel Stent), Travoprost, NCX 470, and others.
• Open-angle Glaucoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Open-angle Glaucoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Open-angle Glaucoma Treatment landscape in this detailed analysis @ Open-angle Glaucoma Emerging Drugs and Major Players

Table of Contents

• Introduction
• Executive Summary
• Open-Angle Glaucoma: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Open-Angle Glaucoma – DelveInsight’s Analytical Perspective
• In-depth Commercial Assessment
• Open-Angle Glaucoma Collaboration Deals
• Late Stage Products (Phase III)
• NCX 470: Nicox Ophthalmics
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• BTQ-1902: Betaliq, Inc.
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I/II)
• TO-O-1001: Theratocular Biotek
• Drug profiles in the detailed report…..
• Preclinical and Discovery Stage Products
• Product Name: Company Name
• Drug profiles in the detailed report…..
• Inactive Products
• Open-Angle Glaucoma Key Companies
• Open-Angle Glaucoma Key Products
• Open-Angle Glaucoma- Unmet Needs
• Open-Angle Glaucoma- Market Drivers and Barriers
• Open-Angle Glaucoma- Future Perspectives and Conclusion
• Open-Angle Glaucoma Analyst Views
• Open-Angle Glaucoma Key Companies
• Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Hemophagocytic Lymphohistiocytosis Pipeline Insights 2025” report delivers extensive analysis on over 5 companies and more than 5 pipeline drugs in the Hemophagocytic Lymphohistiocytosis treatment arena. It features in-depth profiles of Hemophagocytic Lymphohistiocytosis pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses Hemophagocytic Lymphohistiocytosis therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.

Obtain DelveInsight’s thorough Hemophagocytic Lymphohistiocytosis Pipeline Report to explore emerging treatments, key Hemophagocytic Lymphohistiocytosis Companies, and future Hemophagocytic Lymphohistiocytosis treatment landscapes @ Hemophagocytic Lymphohistiocytosis Pipeline Outlook Report

Key Takeaways from the Hemophagocytic Lymphohistiocytosis Pipeline Report

• On October 16, 2025, St. Jude Children’s Research Hospital conducted a multi-site Phase Ib/II, 2-arm non-randomized clinical trial to assess the effectiveness and tolerability of a response-adapted approach combining ruxolitinib, dexamethasone, and etoposide as initial therapy for newly diagnosed hemophagocytic lymphohistiocytosis (HLH) or as rescue therapy for relapsed/refractory HLH.
• On October 14, 2025, Electra Therapeutics Inc. organized a trial with two parts: Phase 1b (Part 1) and Phase 2/3 (Part 2). Part 1 aims to evaluate the safety, effectiveness, pharmacodynamics, and pharmacokinetics of ELA026 in pediatric and adult participants with treatment-naive (TN) and relapsed/refractory sHLH. The primary goals of Part 1 are to establish the safety of ELA026 given intravenously (IV) and subcutaneously (SC) to sHLH patients and to determine the recommended Phase 3 dose and schedule for ELA026. Participants will enroll in a dose-escalating cohort (Cohort 1) followed by two fixed dose cohorts (Cohorts 2-3) treated for 12 weeks.
• DelveInsight’s Hemophagocytic Lymphohistiocytosis pipeline report showcases a dynamic field with over 5 active contributors developing more than 5 pipeline treatments for Hemophagocytic Lymphohistiocytosis care.
• The top Hemophagocytic Lymphohistiocytosis Companies include Chia Tai Tianqing Pharmaceutical Group, Bellicum Pharmaceuticals, Atara Biotherapeutics, Incyte Corporation, Alpine Immune Sciences, Expression Therapeutics, and others.
• Promising Hemophagocytic Lymphohistiocytosis Therapies include Ruxolitinib, Dexamethasone, Etoposide, Emapalumab, Dexamethasone, NI-0501, and others.

Access DelveInsight’s in-depth Hemophagocytic Lymphohistiocytosis Pipeline Analysis for a closer look at promising breakthroughs @ Hemophagocytic Lymphohistiocytosis Clinical Trials and Studies

Hemophagocytic Lymphohistiocytosis Overview

Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal disorder stemming from an overactive, aberrant immune response. The immune system serves as the body’s defense against foreign invaders or substances. Hemophagocytic lymphohistiocytosis (HLH) has various underlying causes. Multiple terms describe this condition. Familial hemophagocytic lymphohistiocytosis (FHL) denotes genetic variants caused by a defective gene.

Hemophagocytic Lymphohistiocytosis Emerging Drugs Profile

• Tabelecleucel: Atara Biotherapeutics

Tabelecleucel is a T cell therapy. It is currently in Phase II development for Haemophagocytic lymphohistiocytosis by Atara Biotherapeutics.

• TQ05105: Chia Tai Tianqing Pharmaceutical Group

TQ-05105 is an inhibitor of Janus kinase-2. It is currently in Phase I trials for Haemophagocytic lymphohistiocytosis by Chia Tai Tianqing Pharmaceutical Group.

The Hemophagocytic Lymphohistiocytosis pipeline report provides insights into

• The report furnishes comprehensive details on organizations advancing therapies for Hemophagocytic Lymphohistiocytosis, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Hemophagocytic Lymphohistiocytosis management.
• Hemophagocytic Lymphohistiocytosis Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Hemophagocytic Lymphohistiocytosis Drugs in progress, sorted by development phase, administration route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Hemophagocytic Lymphohistiocytosis market.

Get a detailed analysis of the latest innovations in the Hemophagocytic Lymphohistiocytosis pipeline. Explore DelveInsight’s expert-driven report today! @ Hemophagocytic Lymphohistiocytosis Unmet Needs

Hemophagocytic Lymphohistiocytosis Companies

Chia Tai Tianqing Pharmaceutical Group, Bellicum Pharmaceuticals, Atara Biotherapeutics, Incyte Corporation, Alpine Immune Sciences, Expression Therapeutics, and others.

Hemophagocytic Lymphohistiocytosis pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical
• Molecule Type

Hemophagocytic Lymphohistiocytosis Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Product Type

Obtain DelveInsight’s latest report to gain strategic insights into upcoming Hemophagocytic Lymphohistiocytosis Therapies and key Hemophagocytic Lymphohistiocytosis Developments @ Hemophagocytic Lymphohistiocytosis Market Drivers and Barriers, and Future Perspectives

Scope of the Hemophagocytic Lymphohistiocytosis Pipeline Report

• Coverage- Global
• Hemophagocytic Lymphohistiocytosis Companies- Chia Tai Tianqing Pharmaceutical Group, Bellicum Pharmaceuticals, Atara Biotherapeutics, Incyte Corporation, Alpine Immune Sciences, Expression Therapeutics, and others.
• Hemophagocytic Lymphohistiocytosis Therapies- Ruxolitinib, Dexamethasone, Etoposide, Emapalumab, Dexamethasone, NI-0501, and others.
• Hemophagocytic Lymphohistiocytosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hemophagocytic Lymphohistiocytosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Hemophagocytic Lymphohistiocytosis drug development? Find out in DelveInsight’s exclusive Hemophagocytic Lymphohistiocytosis Pipeline Report-access it now! @ Hemophagocytic Lymphohistiocytosis Emerging Drugs and Major Companies

Table of Content

• Introduction
• Executive Summary
• Hemophagocytic Lymphohistiocytosis: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Late Stage Products (Phase III)
• Drug Name: Company Name
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• Tabelecleucel: Atara Biotherapeutics
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I)
• TQ05105: Chia Tai Tianqing Pharmaceutical Group Co
• Drug profiles in the detailed report…..
• Preclinical Stage Products
• ALPN-101: Alpine Immune Sciences
• Drug profiles in the detailed report…..
• Inactive Products
• Hemophagocytic Lymphohistiocytosis Key Companies
• Hemophagocytic Lymphohistiocytosis Key Products
• Hemophagocytic Lymphohistiocytosis- Unmet Needs
• Hemophagocytic Lymphohistiocytosis- Market Drivers and Barriers
• Hemophagocytic Lymphohistiocytosis- Future Perspectives and Conclusion
• Hemophagocytic Lymphohistiocytosis Analyst Views
• Hemophagocytic Lymphohistiocytosis Key Companies
• Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

 

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Lupus Nephritis Pipeline Insight 2025” report delivers extensive analysis on over 35 companies and more than 40 pipeline drugs in the Lupus Nephritis treatment arena. It includes thorough profiles of Lupus Nephritis Pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Lupus Nephritis Pipeline Therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Curious about the latest updates in the Lupus Nephritis Pipeline? Click here to explore the therapies and trials making headlines @ Lupus Nephritis Pipeline Outlook Report

Key Takeaways from the Lupus Nephritis Pipeline Report

• On October 27, 2025, Novartis Pharmaceuticals disclosed a trial to assess the effectiveness and safety of rapcabtagene autoleucel (given once after lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
• On October 20, 2025, AstraZeneca conducted a trial to evaluate the effectiveness and safety of anifrolumab versus placebo as an addition to SOC (including MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (with or without concomitant Class V). The total study duration may reach up to approximately 116 weeks, including Screening and Follow-up. About 360 participants will be randomized 1:1 to receive anifrolumab or matching placebo during the Treatment Period.
• On October 20, 2025, HI-Bio, A Biogen Company organized a trial to see how felzartamab affects individuals with LN. Felzartamab is a monoclonal antibody, meaning it’s an antibody produced in a lab. Felzartamab can target immune cells that generate antibodies, aiding in reducing their accumulation in the kidneys. The primary aim is to understand the safety of felzartamab and its effects in the body of LN patients on standard care. This will guide decisions on further studies with felzartamab in LN patients. Standard care refers to the typical treatment or management provided for a condition, as directed by their physician.
• DelveInsight’s Lupus Nephritis Pipeline report illustrates a vibrant arena with over 35 active contributors developing more than 40 pipeline treatments for Lupus Nephritis care.
• The prominent Lupus Nephritis Companies include Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others.
• Promising Lupus Nephritis Therapies include Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394), and others.

Want to know which companies are leading innovation in Lupus Nephritis? Dive into the full pipeline insights @ Lupus Nephritis Clinical Trials Assessment

The Lupus Nephritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Lupus Nephritis Pipeline Report also highlights the unmet needs with respect to the Lupus Nephritis.

Lupus Nephritis Overview

Lupus Nephritis (LN) is among the most serious organ complications of systemic lupus erythematosus (SLE), an autoimmune condition that leads to loss of immune tolerance to endogenous nuclear material, resulting in widespread autoimmunity that harms multiple tissues and organs. The overall incidence and prevalence of SLE range from 7.4-159.4 cases per 100,000 people and 1.4 to 21.9%, respectively. According to the National Kidney Foundation, Lupus nephritis (LN) is a type of glomerulonephritis that causes inflammation (swelling or scarring) of the tiny blood vessels that filter wastes in the kidney (glomeruli) and occasionally the kidneys themselves. Histologically, LN is divided into six classes reflecting different manifestations and severity of renal involvement in SLE. Lupus nephritis can lead to permanent kidney damage, known as chronic kidney disease or CKD. The most severe form is proliferative nephritis, which can scar the kidneys. These scars can impair kidney function and lead to kidney failure or end-stage renal disease (ESRD).

Lupus Nephritis Emerging Drugs Profile

• Obinutuzumab: Hoffmann-La Roche

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, developed by GlycArt Biotechnology AG and Roche. Obinutuzumab operates differently from type I anti-CD20 antibodies like rituximab, mainly by triggering direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is being tested in a broad program of clinical trials for B-cell malignancies. Obinutuzumab may trigger severe infusion-related reactions during or up to 24 hours after administration. These reactions are more common with the first and second doses. The drug is currently in Phase III trials for lupus nephritis.

• ADX-097: Q32 Bio

ADX-097 leverages a novel platform for tissue-targeted modulation of the complement system without prolonged systemic inhibition, distinguishing it from existing complement therapies. Q32 Bio finished a first-in-human, Phase I escalating dose clinical study of ADX-097 in healthy volunteers. Outcomes from the Phase I trial showed favorable tolerability and immunogenicity across all single and multiple dose groups, with weekly subcutaneous dosing achieving levels for complete complement blockade in tissues without systemic effects. The drug is in Phase II development for Lupus Nephritis.

• NKX019: Nkarta

NKX019 targets CD19-positive B cells, crucial in autoimmune diseases like lupus. The treatment uses NK cells from healthy donors, genetically engineered to better eliminate these B cells. Notably, NKX019 includes a membrane-bound interleukin-15 form, potentially enhancing NK cell persistence and function without extensive cytokine support. It is in Phase I trials for Lupus Nephritis.

If you’re tracking ongoing Lupus Nephritis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Lupus Nephritis Treatment Drugs

The Lupus Nephritis Pipeline report provides insights into:-

• The report furnishes comprehensive details on organizations advancing therapies for Lupus Nephritis, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Lupus Nephritis management.
• Lupus Nephritis Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Lupus Nephritis Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Lupus Nephritis market.

Lupus Nephritis Companies

Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others.

Lupus Nephritis Pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Lupus Nephritis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Lupus Nephritis Pipeline Report covers it all – check it out now @ Lupus Nephritis Market Drivers and Barriers, and Future Perspectives

Scope of the Lupus Nephritis Pipeline Report

• Coverage- Global
• Lupus Nephritis Companies- Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others.
• Lupus Nephritis Therapies- Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394), and others.
• Lupus Nephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Lupus Nephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Lupus Nephritis Treatment landscape in this detailed analysis @ Lupus Nephritis Emerging Drugs and Major Players

Table of Contents

• Introduction
• Executive Summary
• Lupus Nephritis: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Lupus Nephritis- DelveInsight’s Analytical Perspective
• Late Stage Products (Phase III)
• Obinutuzumab: Hoffmann-La Roche
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• ADX-097: Q32 Bio
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I)
• NKX019: Nkarta
• Drug profiles in the detailed report…..
• Preclinical and Discovery Stage Products
• Drug name: Company name
• Drug profiles in the detailed report…..
• Inactive Products
• Lupus Nephritis Key Companies
• Lupus Nephritis Key Products
• Lupus Nephritis- Unmet Needs
• Lupus Nephritis- Market Drivers and Barriers
• Lupus Nephritis- Future Perspectives and Conclusion
• Lupus Nephritis Analyst Views
• Lupus Nephritis Key Companies
• Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

 

Kanishk

kkumar@delveinsight.com

DelveInsight’s “Lupus Nephritis Pipeline Insight 2025” report delivers extensive analysis on over 35 companies and more than 40 pipeline drugs in the Lupus Nephritis treatment arena. It includes thorough profiles of Lupus Nephritis Pipeline drugs, encompassing clinical and nonclinical development stages. Additionally, it evaluates Lupus Nephritis Pipeline Therapeutics by product category, development phase, administration method, and molecular structure. It also points out discontinued pipeline products in this domain.

Curious about the latest updates in the Lupus Nephritis Pipeline? Click here to explore the therapies and trials making headlines @ Lupus Nephritis Pipeline Outlook Report

Key Takeaways from the Lupus Nephritis Pipeline Report

• On October 27, 2025, Novartis Pharmaceuticals disclosed a trial to assess the effectiveness and safety of rapcabtagene autoleucel (given once after lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
• On October 20, 2025, AstraZeneca conducted a trial to evaluate the effectiveness and safety of anifrolumab versus placebo as an addition to SOC (including MMF and glucocorticoids) in adults with active proliferative Class III or Class IV LN (with or without concomitant Class V). The total study duration may reach up to approximately 116 weeks, including Screening and Follow-up. About 360 participants will be randomized 1:1 to receive anifrolumab or matching placebo during the Treatment Period.
• On October 20, 2025, HI-Bio, A Biogen Company organized a trial to see how felzartamab affects individuals with LN. Felzartamab is a monoclonal antibody, meaning it’s an antibody produced in a lab. Felzartamab can target immune cells that generate antibodies, aiding in reducing their accumulation in the kidneys. The primary aim is to understand the safety of felzartamab and its effects in the body of LN patients on standard care. This will guide decisions on further studies with felzartamab in LN patients. Standard care refers to the typical treatment or management provided for a condition, as directed by their physician.
• DelveInsight’s Lupus Nephritis Pipeline report illustrates a vibrant arena with over 35 active contributors developing more than 40 pipeline treatments for Lupus Nephritis care.
• The prominent Lupus Nephritis Companies include Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others.
• Promising Lupus Nephritis Therapies include Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394), and others.

Want to know which companies are leading innovation in Lupus Nephritis? Dive into the full pipeline insights @ Lupus Nephritis Clinical Trials Assessment

The Lupus Nephritis Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Lupus Nephritis Pipeline Report also highlights the unmet needs with respect to the Lupus Nephritis.

Lupus Nephritis Overview

Lupus Nephritis (LN) is among the most serious organ complications of systemic lupus erythematosus (SLE), an autoimmune condition that leads to loss of immune tolerance to endogenous nuclear material, resulting in widespread autoimmunity that harms multiple tissues and organs. The overall incidence and prevalence of SLE range from 7.4-159.4 cases per 100,000 people and 1.4 to 21.9%, respectively. According to the National Kidney Foundation, Lupus nephritis (LN) is a type of glomerulonephritis that causes inflammation (swelling or scarring) of the tiny blood vessels that filter wastes in the kidney (glomeruli) and occasionally the kidneys themselves. Histologically, LN is divided into six classes reflecting different manifestations and severity of renal involvement in SLE. Lupus nephritis can lead to permanent kidney damage, known as chronic kidney disease or CKD. The most severe form is proliferative nephritis, which can scar the kidneys. These scars can impair kidney function and lead to kidney failure or end-stage renal disease (ESRD).

Lupus Nephritis Emerging Drugs Profile

• Obinutuzumab: Hoffmann-La Roche

Obinutuzumab is a humanized anti-CD20 monoclonal antibody, developed by GlycArt Biotechnology AG and Roche. Obinutuzumab operates differently from type I anti-CD20 antibodies like rituximab, mainly by triggering direct cell death and antibody-dependent cell-mediated cytotoxicity. Obinutuzumab is being tested in a broad program of clinical trials for B-cell malignancies. Obinutuzumab may trigger severe infusion-related reactions during or up to 24 hours after administration. These reactions are more common with the first and second doses. The drug is currently in Phase III trials for lupus nephritis.

• ADX-097: Q32 Bio

ADX-097 leverages a novel platform for tissue-targeted modulation of the complement system without prolonged systemic inhibition, distinguishing it from existing complement therapies. Q32 Bio finished a first-in-human, Phase I escalating dose clinical study of ADX-097 in healthy volunteers. Outcomes from the Phase I trial showed favorable tolerability and immunogenicity across all single and multiple dose groups, with weekly subcutaneous dosing achieving levels for complete complement blockade in tissues without systemic effects. The drug is in Phase II development for Lupus Nephritis.

• NKX019: Nkarta

NKX019 targets CD19-positive B cells, crucial in autoimmune diseases like lupus. The treatment uses NK cells from healthy donors, genetically engineered to better eliminate these B cells. Notably, NKX019 includes a membrane-bound interleukin-15 form, potentially enhancing NK cell persistence and function without extensive cytokine support. It is in Phase I trials for Lupus Nephritis.

If you’re tracking ongoing Lupus Nephritis Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Lupus Nephritis Treatment Drugs

The Lupus Nephritis Pipeline report provides insights into:-

• The report furnishes comprehensive details on organizations advancing therapies for Lupus Nephritis, including the total treatments each company is developing.
• It examines various therapeutic candidates categorized into initial, intermediate, and advanced development stages for Lupus Nephritis management.
• Lupus Nephritis Companies are engaged in precision therapeutics with ongoing and paused (inactive or halted) initiatives.
• Lupus Nephritis Drugs in progress, sorted by development phase, delivery route, target receptor, standalone or combined therapy, unique action mechanisms, and molecular category.
• Comprehensive review of partnerships (corporate alliances and academic ties), licensing deals, and funding information to drive future growth in the Lupus Nephritis market.

Lupus Nephritis Companies

Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others.

Lupus Nephritis Pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Lupus Nephritis Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Lupus Nephritis Pipeline Report covers it all – check it out now @ Lupus Nephritis Market Drivers and Barriers, and Future Perspectives

Scope of the Lupus Nephritis Pipeline Report

• Coverage- Global
• Lupus Nephritis Companies- Hoffmann-La Roche, Qilu Pharmaceutical, Vera Therapeutics, Kyverna Therapeutics, Cabaletta Bio, Takeda, Nkarta Therapeutics, Annexon, Century Therapeutics, Lepton Pharmaceuticals, Transcenta Holding, Inflection Biosciences, and others.
• Lupus Nephritis Therapies- Ciclesonide, Niclosamide, Povetacicept, APL-2, Belimumab Injection, AZD0120, Cyclophosphamide, Fludarabine, AZD0120, Abetimus sodium (LJP 394), and others.
• Lupus Nephritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Lupus Nephritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Lupus Nephritis Treatment landscape in this detailed analysis @ Lupus Nephritis Emerging Drugs and Major Players

Table of Contents

• Introduction
• Executive Summary
• Lupus Nephritis: Overview
• Pipeline Therapeutics
• Therapeutic Assessment
• Lupus Nephritis- DelveInsight’s Analytical Perspective
• Late Stage Products (Phase III)
• Obinutuzumab: Hoffmann-La Roche
• Drug profiles in the detailed report…..
• Mid Stage Products (Phase II)
• ADX-097: Q32 Bio
• Drug profiles in the detailed report…..
• Early Stage Products (Phase I)
• NKX019: Nkarta
• Drug profiles in the detailed report…..
• Preclinical and Discovery Stage Products
• Drug name: Company name
• Drug profiles in the detailed report…..
• Inactive Products
• Lupus Nephritis Key Companies
• Lupus Nephritis Key Products
• Lupus Nephritis- Unmet Needs
• Lupus Nephritis- Market Drivers and Barriers
• Lupus Nephritis- Future Perspectives and Conclusion
• Lupus Nephritis Analyst Views
• Lupus Nephritis Key Companies
• Appendix

About Us

DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.

Contact Us

Kanishk

kkumar@delveinsight.com

As per DelveInsight’s evaluation, the global Hypertension pipeline includes over 80 key companies actively developing more than 100 Hypertension treatment therapies, with analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments by DelveInsight.

“Hypertension Pipeline Insight, 2025 report by DelveInsight provides thorough insights into the current clinical development landscape and growth opportunities in the Hypertension Market.

The Hypertension Pipeline report includes in-depth commercial and clinical assessment of pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Hypertension Pipeline Report:

• Companies worldwide are diligently working toward developing novel Hypertension treatment therapies with a considerable amount of success over the years.
• Hypertension companies working in the treatment market are Addpharma Inc., Alnylam Therapeutics, ORPHAI THERAPEUTICS, 35Pharma Inc., Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others, are developing therapies for the Hypertension treatment
• Emerging Hypertension therapies in the different phases of clinical trials are- AD-209, Zilebesiran, LAM-001, HS135, AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others are expected to have a significant impact on the Hypertension market in the coming years.
• In September 2025, AllRock Bio Inc., a clinical-stage biotech company developing therapies for cardiopulmonary and fibrotic diseases, announced a $50 million Series A financing round co-led by Versant Ventures and Westlake BioPartners. The funding will support the advancement of its lead candidate, ROC-101-an oral, first-in-class pan-rho-associated protein kinase (ROCK) inhibitor exclusively licensed from Sanofi-into Phase 2 clinical trials. ROC-101 is being developed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (ILD-PH), both life-threatening conditions with poor five-year survival rates of 57% and 38%. By targeting inflammatory, proliferative, and fibrotic remodeling driven by both ROCK1 and ROCK2, ROC-101 holds promise to meet a major unmet need in these patient populations.
• In August 2025, Cereno Scientific’s lead candidate, CS1, was granted FDA Fast Track designation for pulmonary arterial hypertension, acknowledging its promise as a novel and potentially disease-modifying therapy for this rare and severe condition.
• In August 2025, VASTHERA Co., Ltd. announced FDA clearance of its Investigational New Drug (IND) application to begin a Phase 1 trial for VTB-10, a novel candidate for pulmonary arterial hypertension (PAH). Developed via the company’s proprietary Redoxizyme Trademark platform, VTB-10 is a first-in-class small molecule enzyme (Chemzyme) designed to mimic the function of peroxiredoxin (PRX), which is deficient in PAH lesions. Preclinical data showed that VTB-10 not only reversed abnormal vascular remodeling but also restored healthy endothelial function, offering a dual mechanism of action that sets it apart from current treatment options.
• In March 2025, Merck (NYSE: MRK), also known as MSD outside the U.S. and Canada, has shared initial results from its Phase 3 ZENITH trial evaluating WINREVAIR Trademark (sotatercept-csrk) versus placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), classified as WHO functional class III or IV and at high risk of mortality, despite receiving the maximum tolerated background PAH therapy. With a median follow-up of 10.6 months (range: 0.3-26.1), WINREVAIR significantly reduced the relative risk of major morbidity and mortality events-including all-cause death, lung transplantation, or PAH-related hospitalization ( greater than or equal to 24 hours)-by 76% (HR=0.24 [95% CI, 0.13-0.43]; p
• In January 2025, Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced preliminary findings from its Phase 3 ZENITH trial assessing WINREVAIR Trademark (sotatercept-csrk) against placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH), specifically those categorized as WHO functional class III or IV and considered at high risk of mortality despite being on optimized background PAH treatment. Over a median follow-up period of 10.6 months (range: 0.3-26.1), WINREVAIR demonstrated a 76% reduction in the relative risk of major morbidity and mortality events-defined as all-cause death, lung transplant, or PAH-related hospitalization lasting 24 hours or more-compared to placebo (HR=0.24 [95% CI, 0.13-0.43]; p

Hypertension Overview

Hypertension, commonly known as high blood pressure, is a chronic medical condition in which the force of blood against the artery walls remains consistently elevated. Over time, this increased pressure can strain the heart and blood vessels, leading to serious health problems such as heart disease, stroke, kidney damage, and vision loss. It is often called a “silent killer” because it may not cause noticeable symptoms until complications arise. Hypertension is typically managed through lifestyle changes-like a healthy diet, regular exercise, and reduced salt intake-and medications to help control blood pressure levels.

Get a Free Sample PDF Report to know more about Hypertension Pipeline Therapeutic Assessment

Emerging Hypertension Drugs Under Different Phases of Clinical Development Include:

• AD-209: Addpharma Inc.
• Zilebesiran: Alnylam Therapeutics
• LAM-001: ORPHAI THERAPEUTICS
• HS135: 35Pharma Inc.
• TYVASO/TYVASO DPI/TREPROST Inhalation Solution (treprostinil): United Therapeutics/Mochida Pharmaceutical
• OPSYNVI/YUVANCI (macitentan and tadalafil): Johnson & Johnson
• WINREVAIR (sotatercept): Merck
• UPTRAVI (selexipag): Johnson & Johnson/ Nippon Shinyaku
• AV-101: Aerovate Therapeutics
• LTP001: Novartis
• KER-012: Keros Therapeutics
• TPN171H: Vigonvita Life Sciences
• Treprostinil Palmitil: Insmed Incorporated
• Satralizumab (Genetical Recombination): Chugai Pharmaceutical
• Sotatercept: Merck Sharp & Dohme
• Macitentan: Janssen Pharmaceutical
• ACT-293987: Actelion
• GB002 (seralutinib): Gossamer Bio
• Parenteral Treprostinil: Lung Biotechnology PBC
• Ralinepag: United Therapeutics
• Selonsertib: Gilead Sciences
• Sotatercept: Acceleron Pharma
• ubenimex: Eiger BioPharmaceuticals
• Olaparib: AstraZeneca

Hypertension Route of Administration

Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Hypertension Molecule Type

Hypertension Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Hypertension Pipeline Therapeutics Assessment

• Hypertension Assessment by Product Type
• Hypertension By Stage and Product Type
• Hypertension Assessment by Route of Administration
• Hypertension By Stage and Route of Administration
• Hypertension Assessment by Molecule Type
• Hypertension by Stage and Molecule Type

DelveInsight’s Hypertension Report covers around 100+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Hypertension product details are provided in the report. Download the Hypertension pipeline report to learn more about the emerging Hypertension therapies

Some of the key companies in the Hypertension Therapeutics Market include:

Key companies developing therapies for Hypertension are – VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, Antlia Bioscience Inc, and others.

Hypertension Pipeline Analysis:

The Hypertension pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hypertension Treatment.
• Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Hypertension drugs and therapies

Hypertension Pipeline Market Drivers

• Rising prevalence of Hypertension worldwide, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Hypertension Market.

Hypertension Pipeline Market Barriers

• However, high cost associated with the treatment of Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Hypertension Market growth.

Scope of Hypertension Pipeline Drug Insight

• Coverage: Global
• Key Hypertension Companies: Addpharma Inc., Alnylam Therapeutics, ORPHAI THERAPEUTICS, 35Pharma Inc., Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others
• Key Hypertension Therapies: AD-209, Zilebesiran, LAM-001, HS135, AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others
• Hypertension Therapeutic Assessment: Hypertension current marketed and Hypertension emerging therapies
• Hypertension Market Dynamics: Hypertension market drivers and Hypertension market barriers

Request for Sample PDF Report for Hypertension Pipeline Assessment and clinical trials

Table of Contents

1. Hypertension Report Introduction
2. Hypertension Executive Summary
3. Hypertension Overview
4. Hypertension- Analytical Perspective In-depth Commercial Assessment
5. Hypertension Pipeline Therapeutics
6. Hypertension Late Stage Products (Phase II/III)
7. Hypertension Mid Stage Products (Phase II)
8. Hypertension Early Stage Products (Phase I)
9. Hypertension Preclinical Stage Products
10. Hypertension Therapeutics Assessment
11. Hypertension Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Hypertension Key Companies
14. Hypertension Key Products
15. Hypertension Unmet Needs

16 . Hypertension Market Drivers and Barriers

1. Hypertension Future Perspectives and Conclusion
2. Hypertension Analyst Views
3. Appendix
4. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us

 

Kanishk

kkumar@delveinsight.com